SARS-CoV-2 IgG Antibody Response after Immunization of Healthcare Workers with Inactivated COVID-19 Vaccine (CoronaVac) at Phyathai 3 Hospital
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To evaluate the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) anti-spike Immunoglobulin G (IgG) antibody response after CoronoVac immunization of healthcare workers at Phyathai 3 Hospital.
MATERIALS AND METHODS: The descriptive study was performed at Phyathai 3 Hospital between March 2021 and May 2021. Healthcare workers who received two doses (three weeks apart) of the CoronaVac vaccine were included. Blood samples for anti-spike IgG antibodies were taken from each healthcare worker before getting vaccinated and four weeks after completing two doses of the vaccine.
RESULT: A total of 88 healthcare workers were enrolled in our study. Fifty-three (60%) of them were female, 84(95%) were physicians, 46(52%) were obese and 33(37.5%) had at least one coexisting condition. The mean age was 45.8 ± 9.3 years. Seven (8%) of participants were older than 60 years of age. All participants did not have IgG antibodies at baseline. Eighty-seven (98.9%) healthcare workers had seroconversion of anti-spike IgG antibodies four weeks after completing two doses of the CoronaVac vaccine. The mean level of anti-spike IgG at four weeks after completing vaccination was 115+/-85 unit/ml (range, 1.77-297.3 unit/ml). Anti-spike IgG levels were significantly higher in females than males (p = 0.02). Normal-weight participants showed higher anti-spike IgG levels than obese individuals (p = 0.01). IgG antibody responses tended to decrease with age. The highest IgG levels were observed in the ages of 30-40 years. CONCLUSION: Two doses of the CoronaVac vaccine could induce a 98.9% rate of seroconversion in healthcare workers. Female and normal-weight participants were significantly associated with a higher level of IgG response. Younger adults had a higher immune response than older adults in our setting.
Article Details
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. (Accessed on May 14, 2021, at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance ).
Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. 2019. (Accessed on May 14, 2021, at https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html ).
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497.
Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med 2021;174:69.
World Health Organization. Transmission of SARS-CoV-2: Implications for infection prevention precautions. (Accessed on May 14, 2021, at https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations ).
Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating COVID-19. Infect Control Hosp Epidemiol 2020;41(9):1064-5.
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181-92.
Sinovac. Sinovac Announces Phase III Results of its COVID-19 Vaccine. (Accessed on February 5, 2021, at http://www.sinovac.com/?optionid=754&auto_id=922b ).
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020: 586(7830):589-93.
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—Preliminary report. N Engl J Med 2020; 383:1920-31.
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396:
–78.